Activity and safety of atezolizumab plus carboplatin and paclitaxel in patients with advanced or recurrent thymic carcinoma (MARBLE): a multicentre, single-arm, phase 2 trial
Takehito Shukuya(Juntendo University), Kazuhisa Takahashi(Juntendo University), Yukina Shirai(Juntendo University), Kyoichi Kaira(Saitama International Medical Center), Koichi Takayama(Kyoto Prefectural University of Medicine), Yasushi Goto(National Cancer Center Hospital East), Tomoyasu Mimori, Takuo Hayashi(Juntendo University), Tetsuhiko Asao(Cornell University), Yoshitaka Zenke(National Cancer Center Hospital East), Junko Tanizaki(Kindai University Sakai Hospital), Keita Mori(Shizuoka Cancer Center), Shunichi Sugawara(Sendai Kousei Hospital), Hiroshi Tanaka(Tokyo Medical and Dental University), Takuji Suzuki(Chiba University), Ryo Ko(Shizuoka Cancer Center), Yoshihiro Amano(Shimane University), Motoko Tachihara(Kobe University)
Cited by 20
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695